Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT02873338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with acute myeloid leukemia (AML) when compared with subjects receiving standard induction chemotherapy alone.
Study identification
- NCT ID
- NCT02873338
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2016 (Actual)
- Primary completion
- Jun 2019 (Actual)
- Completion
- Jun 2019 (Actual)
- Last update posted
- Sep 7, 2023
2016 – 2019
United States locations
- U.S. sites
- 23
- U.S. states
- 20
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego, Moores Cancer Center | La Jolla | California | 92093 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| George Washington University | Washington D.C. | District of Columbia | 20037 | — |
| Franciscan St. Francis Health | Indianapolis | Indiana | 46237 | — |
| June E. Nylen Cancer Center | Sioux City | Iowa | 51101 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Tulane University/Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Allina Health - Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87131 | — |
| Northwell Health, Monter Cancer Center | Lake Success | New York | 11042 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Oregon Health & Science University Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Tennessee Oncology/Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Methodist Healthcare System of San Antonio | San Antonio | Texas | 78229 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02873338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2023 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02873338 live on ClinicalTrials.gov.